Summary
Pacira Pharmaceuticals Inc (Pacira) discoveres, develops, manufactures and commercializes drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. Its other products developed under partnerships include DepoCyt (cytarabine liposome injection) for lymphomatous meningitis; and Nocita (bupivacaine liposome injectable suspension) for surgical infiltration in dogs. Its products are used by hospitals and ambulatory surgery centers. The company sells its products through co-promotion agreements and supply agreements with other pharma companies. Pacira is headquartered in Parsippany, New Jersey, the US.
Pacira Pharmaceuticals Inc (PCRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 11
Licensing Agreements 12
Pacira Pharma Enters into Licensing Agreement with Aratana Therapeutics 12
Pacira Pharma Enters Into Licensing Agreement With Novo Nordisk 13
Equity Offering 14
Pacira Pharma Completes Public Offering Of Shares For US$117.8 Million 14
Pacira Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$67 Million 15
Pacira Pharma Completes Underwritten Public Offering Of Common Stock For US$52 Million 17
Pacira Pharma Completes IPO For US$42 Million 18
Debt Offering 20
Pacira Pharma Raises USD345 Million in Private Placement of Notes Due 2022 20
Pacira Pharma Completes Private Placement Of Notes Due 2019 For US$120 Million 21
Pacira Pharmaceuticals Inc - Key Competitors 23
Key Employees 24
Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Mar 01, 2017: Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update 26
Jan 06, 2017: Pacira Pharmaceuticals Reports Preliminary 2016 Revenues of $276.4 Million 28
Aug 04, 2016: Pacira Pharmaceuticals Reports Second Quarter 2016 Financial Results 29
May 02, 2016: Pacira Pharmaceuticals Reports First Quarter 2016 Financial Results 31
Feb 25, 2016: Pacira Pharmaceuticals Reports 2015 Financial Results 32
Jan 07, 2016: Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million 34
Corporate Communications 35
Jun 15, 2017: Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors 35
May 23, 2017: Pacira Pharmaceuticals Announces Resignation of James Scibetta 36
Apr 19, 2016: Pacira Pharmaceuticals Appoints Charles A. Reinhart III as Chief Financial Officer 37
Apr 05, 2016: Pacira Pharmaceuticals Appoints Robert Weiland as Chief Commercial Officer 38
Product News 39
Nov 11, 2016: Pacira Pharmaceuticals Unveils Virtual Reality Training Simulation to Enhance Administration Technique Education for EXPAREL in Total Knee Replacement Surgery 39
Sep 21, 2016: Pacira Pharmaceuticals Announces Official Launch of EXPAREL to the Oral Surgeon Community to Treat Pain Following Oral and Maxillofacial Procedures 40
Aug 05, 2016: US$8 million Exparel sales milestone from Pacira triggered 42
Mar 14, 2017: Phase 4 Study Shows EXPAREL Versus an Active Comparator Significantly Reduces Opioid Consumption and Postsurgical Pain in Patients Undergoing Total Knee Arthroplasty 43
Mar 01, 2016: New Analysis Shows Use of EXPAREL Reduces Length of Hospital Stay and Improves Discharge Status Compared to Standard Analgesic Modality in Total Knee Arthroplasty 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
List of Tables
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pacira Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 11
Pacira Pharma Enters into Licensing Agreement with Aratana Therapeutics 12
Pacira Pharma Enters Into Licensing Agreement With Novo Nordisk 13
Pacira Pharma Completes Public Offering Of Shares For US$117.8 Million 14
Pacira Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$67 Million 15
Pacira Pharma Completes Underwritten Public Offering Of Common Stock For US$52 Million 17
Pacira Pharma Completes IPO For US$42 Million 18
Pacira Pharma Raises USD345 Million in Private Placement of Notes Due 2022 20
Pacira Pharma Completes Private Placement Of Notes Due 2019 For US$120 Million 21
Pacira Pharmaceuticals Inc, Key Competitors 23
Pacira Pharmaceuticals Inc, Key Employees 24
Pacira Pharmaceuticals Inc, Other Locations 25
Pacira Pharmaceuticals Inc, Subsidiaries 25List of Figures
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
